|
August 17th, 2005
Triage Wireless, developer of the AdvancedBPM System
cuffless blood pressure system, closed a $3 million Series A funding round as a result of investments from 3i and Sanderling.
The cuffless technology from Triage addresses the emerging
telemedicine market. Their system includes a monitoring patch, designed for comfort, to remotely monitor, record and evaluate
blood pressure and other vital signs. The technology is expected to become an effective tool for cardiac disease management
as well as serve as a 24-hour ambulatory monitor.
Matthew Banet, CEO of Triage noted differences in its
product compared to older technologies, "Conventional blood pressure monitors, especially 24-hour ambulatory monitors, are
uncomfortable to wear and typically ineffective at continuous monitoring, particularly during work and sleep. Our AdvancedBPM
System offers tremendous benefits to at-risk patients, as well as to an aging population experiencing escalating healthcare
costs, and looking to reduce doctor visits and enhance self-care."
David Aslin, partner with 3i, commented on the
market size and the underlying wireless Internet technology, "Hypertension affects close to 90 million Americans, and about
1 billion individuals worldwide, but the shortcomings of conventional cuff-based blood pressure monitoring make it difficult
to detect and monitor. Triage's AdvancedBPM System combines wireless, sensor, and Internet technologies in the medical field
-- areas in which we have significant expertise. The company has an extraordinary team with a platform that can be applied
to multiple clinical applications -- we look forward to supporting Triage's growth."
Noting that the investment was one of the first
from its new $420 million fund was Tim Wollaeger, Managing Director of Sanderling, "We are pleased to make one of the
first investments from our new $420 million fund, Sanderling VI, with the Triage management team and 3i."
The AdvancedBPM System is used to measure biometric parameters
from a disposable patch sensor that can be worn by a patient twenty-four hours a day. The information measured is transmitted
from the sensor via wireless connection to a web site, where the information can be analyzed and then, if necessary, relayed
to emergency medical personal.
The device and system has the potential to produce an
invaluable database of information related to cardiac disease as a result of its ability to economically monitor vital signs
24 hours a day. Noting the potential of the technology and applications to other medical problems was Robert Murad, MD, Head
of Internal Medicine at Scripps Medical Clinic and Chief Medical Officer of Triage, "The system has incredible potential in
the future, AdvancedBPM System may be used for patients with CHF, sleep apnea, pneumonia and cardiac arrhythmias."
August 11th, 2005
Taylor Madison Corp. (Pink Sheets:TMDN) and its wholly-owned
subsidiary Telzuit Technologies, Inc. have entered into a 12 month agreement with AlphaMedica, a medical education and communications
company, to provide marketing services for its BioPatch Platform. AlphaMedica, as part of the agreement, will market the
BioPatch Wireless Holter Monitor, a 12 lead biopatch wireless heart monitor. The device is expected to be available on the
market sometime in 2005. AlphaMedica is also expected to market Taylor Madison’s other products scheduled for 2006.
Among these is a BioPatch Wireless Cardiac Event Monitor.
Commenting on the selection of AlphaMedica was Donald
Sproat, CEO of Taylor Madison and Telzuit, "AlphaMedica is a quality company that has proven experience in both the cardiovascular
and medical device fields. We are leveraging the same people in their company that work with some of the foremost companies
in the world such as Pfizer, Allergan, Aventis and Forrest Laboratories Inc. I have witnessed their effectiveness firsthand
and believe that their diligence, dedication and creativeness applied in the same manner with BioPatch products will produce
the exposure and use Telzuit is looking for."
The Bio-Patch, according to Telzuit Medical Technologies
is an FDA approved EKG heart-monitoring device intended for the $81billion dollar outpatient heart disease treatment
market. Telzuit completed a private placement for $4.2 million on June 29th, 2005.
|
